U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06899230) titled 'Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of IQ-007' on March 13.
Brief Summary: This is a randomized, double-blind, placebo-controlled study conducted in healthy adult volunteers to assess the safety, tolerability and pharmacokinetics of iQ-007. iQ-007 may be indicated for use in patients with Focal Seizures and Drug-resistant Epilepsy (DRE).
Study Start Date: April 24
Study Type: INTERVENTIONAL
Condition:
Drug Resistant Epilepsy
Focal Seizure
Intervention:
DRUG: iQ-007
Highly selective, orally bioavailable, positive allosteric modulator (PAM) of the excitatory amino acid tr...